IP Library Granted Patent US 10,172,858
Granted Patent B2
US 10,172,858 · App. 15/092,713 · Granted Jan 8, 2019

Combination pharmaceutical compositions and uses thereof

Inventors: Yi Liu (San Diego, CA); Pingda Ren (San Diego, CA); Katayoun Jessen (San Diego, CA); Xin Guo (San Diego, CA); Christian Rommel (Basel, CH)
Assignee: INTELLIKINE LLC
A61K31/519A61K31/337A61K31/436A61K31/52C07D473/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,172,858
App. No.
15/092,713
Granted
Jan 8, 2019
Kind
B2
Abstract

The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.

Claims (9)

1. A method for treating endometrial cancer comprising administering to a subject in need thereof a synergistically effective amount of paclitaxel and a synergistically effective amount of an mTOR inhibitor of formula

or a pharmaceutically acceptable salt thereof, wherein paclitaxel is administered one day before the mTOR inhibitor is administered followed by administration of the mTOR inhibitor once a week or daily for three days.

2. The method of claim 1 , wherein paclitaxel is administered once a week followed by administrations of the mTOR inhibitor daily for three days.

3. The method of claim 1 , wherein paclitaxel is administered once a week followed by administration of the mTOR inhibitor once a week.

4. The method of claim 2 , wherein administration of the mTOR inhibitor for three days is followed by 4 days without administration of the mTOR inhibitor.

5. The method of claim 1 , wherein paclitaxel is administered intravenously and mTOR inhibitor is administered orally.

6. The method of claim 2 , wherein paclitaxel is administered on days 1 and 8 and the mTOR inhibitor is administered on days 2-4 and 9-11 of a fourteen day period.

7. The method of claim 3 , wherein paclitaxel is administered on days 1 and 8 and the mTOR inhibitor is administered on days 2 and 9 of a fourteen day period.

8. The method of claim 6 , wherein paclitaxel is administered on days 1, 8 and 15 of a 28-day cycle and the mTOR inhibitor is administered on days 2-4, 9-11, 16-18, and 23-25 of a 28-day cycle.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2021
From: TAKEDA PHARMACEUTICAL COMPANY LIMITED
To: CALITHERA BIOSCIENCES, INC.
Reel/Frame 058288/0867 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2021
From: INTELLIKINE LLC
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056754/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2016
From: LIU, YI; REN, PINGDA; JESSEN, KATAYOUN; GUO, XIN; ROMMEL, CHRISTIAN
To: INTELLIKINE LLC
Reel/Frame 038491/0114 →
Continuity (3)
Continuation 14113982
Provisional Application 61482568 · May 4, 2011
Related Publication 20160287595A1 · Oct 6, 2016